What's on the label is the measured result — net peptide mass, not gross powder weight, plus RP-HPLC purity, on a lot-numbered COA for every batch.
Net peptide mass and RP-HPLC purity — a lot-numbered COA for every batch.
Net peptide mass + HPLC purity, per lot.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epitalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
Modified GRF 1-29 · GHRH analog
PeptideXpo buyer fit
This page supports buyers comparing CJC-1295 inside a broader GH-axis catalog, including Ipamorelin, Sermorelin, GHRP variants, and CJC-1295 + Ipamorelin combination vials. The buyer intent is assortment planning and OEM sourcing, not a single-molecule analytical monograph.
Overview
CJC-1295 without DAC (also known as Modified GRF 1-29 or ModGRF 1-29) is a 29-amino-acid GHRH analog with four amino-acid substitutions (Ala2→D-Ala, Asn8→Gln, Gly15→Ala, Met27→Leu) that confer protection against DPP-4 cleavage and serum protease degradation. The molecule signals through the GHRH receptor to produce pulsatile GH release that closely resembles physiological secretion patterns, distinct from the more sustained drug-affinity-complex (DAC) version, which has substantially longer plasma half-life via covalent albumin binding. PeptideXpo supplies CJC-1295 no-DAC as the acetate salt, lyophilized, ≥99.0% HPLC. The no-DAC form is most commonly paired with a GHSR-pathway agonist (Ipamorelin, GHRP-2, or GHRP-6) in GH-axis research and compounding workflows, the dual-pathway combination produces additive GH-release signals beyond either component alone, and the canonical CJC-1295 + Ipamorelin blend is one of the most-requested SKUs in our catalog (sold as the dedicated cjc-1295-ipamorelin combination vial). For the full pharmacology rationale of the dual-pathway combination, see our [CJC-1295 + Ipamorelin guide](/insights/cjc-1295-ipamorelin-blend-pharmacology-guide). Compounding pharmacies typically dispense from 2 mg or 5 mg vials; research labs often prefer the 5 mg or 10 mg fills for in vivo dose-titration work.
Who buys this, and why
GH-axis peptides ship to two main buyer types: compounding pharmacies dispensing under physician supervision, and research labs studying somatotropic-axis pharmacology. Pharmacies typically want sterile-filled vials with the full release packet (sterility, endotoxin, CCI); labs typically want bulk lyophilized powder with sequence verification. Blends (the CJC-1295 / Ipamorelin combination is the canonical example) are usually co-lyophilized rather than solution-mixed for potency stability.
Primary buyer fit: academic and contract research laboratories and 503A / 503B compounding pharmacies.
Specifications
Documentation available on request
Regulatory note
Sold as a bulk active for research and for compounding-pharmacy formulation where local regulations permit (notably 503A / 503B in the United States and analogous regimes elsewhere). Not a finished dosage form. Sterile-filled vials are available with full release documentation; the buyer is responsible for verifying scheduling and dispense requirements in the destination market.
Frequently asked questions
Both are based on the same Modified GRF 1-29 core sequence, but the DAC (Drug Affinity Complex) version has a maleimido-propionyl-Lys30 modification that allows covalent binding to serum albumin, dramatically extending plasma half-life from minutes (no-DAC) to roughly a week (DAC). The clinical/research consequence is fundamentally different pharmacokinetic profiles: the no-DAC form produces pulsatile GH release that mimics physiological secretion patterns, while the DAC form produces a sustained elevation that suppresses the natural pulse architecture. Most compounding pharmacy and physiological-research workflows use the no-DAC form; the DAC form is more common in sustained-elevation research contexts.
CJC-1295 signals through the GHRH receptor; Ipamorelin signals through the GHSR (ghrelin receptor). These are two parallel input pathways that both drive somatotroph GH release, and they synergize rather than compete, combining a GHRH-pathway agonist with a GHSR-pathway agonist produces GH-release magnitudes larger than either component alone at comparable individual doses. The standard ratio for the combined product is 1:1 by mass (most commonly 2+2 mg or 5+5 mg per vial). PeptideXpo supplies pre-blended co-lyophilized vials under the cjc-1295-ipamorelin SKU, which is preferred over the buyer mixing the two in solution because the analytical packet certifies the actual ratio in the released vial.
Lyophilized CJC-1295 reconstitutes cleanly in bacteriostatic water for injection at typical research and compounding concentrations. The reconstituted solution is reasonably stable when held at -20 °C as single-use aliquots, but degradation accelerates with freeze-thaw cycling, the operational guidance for the GH-axis class is to aliquot immediately into the smallest workable single-use volumes and limit thaw cycles to three or fewer. The lyophilized vial itself follows the standard 24-month re-test window at -20 °C; the COA carries a documented re-test date for buyers planning recurring orders.
Related peptides
Ghrelin / GHSR pathway GH-release peptide
GH-axis blend (CJC-1295 no DAC + Ipamorelin)
29-mer
GHRH 1-29 fragment
Long-acting GHRH analog with Drug Affinity Complex
